A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination With Ruxolitinib in Patients with Myelofibrosis
In a phase 2 study of INCB050465 plus ruxolitinib in patients with myelofibrosis who previously had a suboptimal or loss of response to ruxolitinib alone, the combination demonstrated preliminary efficacy, and the daily 8-week/then once per week dosing regimen had a better toxicity profile than other PI3K inhibitors have shown.
Blood (ASH Abstract)
In The News
Oncology Nurse Advisor
Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
American Journal of Managed Care
New Guideline Released on Managing Complications in Polycythemia Vera
Oncology Nurse Advisor
Case Study: Myelofibrosis Diagnosis and Early Intervention
In The Literature
Blood (ASH Abstract)
Independent Association of Male Sex With Presentation and Clinical Outcomes in Myeloproliferative Neoplasms
American Journal of Hematology
Myeloproliferative Neoplasms in the Young: Mayo Clinic Experience With 361 Patients Age 40 Years or Younger
European Journal of Haematology
Frequency and Etiology of Pulmonary Hypertension in Patients With Myeloproliferative Neoplasms
New England Journal of Medicine